One-Year Outcomes in Survivors of the Acute Respiratory Distress Syndrome

2003 ◽  
Vol 348 (8) ◽  
pp. 683-693 ◽  
Author(s):  
Margaret S. Herridge ◽  
Angela M. Cheung ◽  
Catherine M. Tansey ◽  
Andrea Matte-Martyn ◽  
Natalia Diaz-Granados ◽  
...  
2014 ◽  
Vol 40 (3) ◽  
pp. 388-396 ◽  
Author(s):  
Chen Yu Wang ◽  
Carolyn S. Calfee ◽  
Devon W. Paul ◽  
David R. Janz ◽  
Addison K. May ◽  
...  

2021 ◽  
Vol 1 (2) ◽  
pp. 147-157
Author(s):  
Siti Rahmah ◽  
Lalu Wahyu Alfian Muharzami ◽  
Lastri Akhdani Almaesy ◽  
Putri Nurhayati ◽  
Ridha Sasmitha A

At the end of 2019, there was a pandemic happening in the world, called the novel Coronavirus disease-19 (COVID-19). Various spectrums of disease from COVID-19, one of which is ARDS. The incidence of COVID-19 in children is not as much as in adults. However, in children under one year of age it can get worse. The main characteristic of worsening infection is the occurrence of ARDS.  Objective: To find out the best treatment for PARDS in COVID-19 patients. Method: The writing of this article uses various sources from scientific journals to government guidelines and related institutions. Search articles using the keywords “Acute Respiratory Distress Syndrome”, “ARDS”, “Pediatric Respiratory Distress Syndrome”, “PARDS”, and “PARDS on COVID-19” Result and Discussion: PARDS was defined based on PALICC in 2015. Pathophysiology of PARDS in COVID-19 patients is still unclear. However, there is a theory that explains the way SARS-Cov-2 enters cells, namely through membrane fusion, giving rise to ARDS. The difference in handling PARDS for COVID-19 patients is that the handling technique is more alert to the risk of aerosols. Conclusions: There are differences in the handling of PARDS for COVID-19 patients in the technique by reducing the risk of virus transmission by preventing leakage when using a ventilator and using a bacterial/virus filter, as well as rescuers and staff using complete PPE during the procedure.


Thorax ◽  
2016 ◽  
Vol 71 (5) ◽  
pp. 401-410 ◽  
Author(s):  
Victor D Dinglas ◽  
Ramona O Hopkins ◽  
Amy W Wozniak ◽  
Catherine L Hough ◽  
Peter E Morris ◽  
...  

2021 ◽  
Author(s):  
David R Price ◽  
Elisa Benedetti ◽  
Katherine Hoffman ◽  
Luis Gomez-Escobar ◽  
Sergio Alvarez-Mulett ◽  
...  

Vascular injury is a menacing element of acute respiratory distress syndrome (ARDS) pathogenesis. To better understand the role of vascular injury in COVID-19 ARDS, we used lung autopsy immunohistochemistry and blood proteomics from COVID-19 subjects at distinct timepoints in disease pathogenesis, including a hospitalized cohort at risk of ARDS development ("at risk", N=59), an intensive care unit cohort with ARDS ("ARDS", N=31), and a cohort recovering from ARDS ("recovery", N=12). COVID-19 ARDS lung autopsy tissue revealed an association between vascular injury and platelet-rich microthrombi. This link guided the derivation of a protein signature in the at risk cohort characterized by lower expression of vascular proteins in subjects who died, an early signal of vascular limitation termed the maladaptive vascular response. These findings were replicated in COVID-19 ARDS subjects, as well as when bacterial and influenza ARDS patients (N=29) were considered, hinting at a common final pathway of vascular injury that is more disease (ARDS) then cause (COVID-19) specific, and may be related to vascular cell death. Among recovery subjects, our vascular signature identified patients with good functional recovery one year later. This vascular injury signature could be used to identify ARDS patients most likely to benefit from vascular targeted therapies.


Sign in / Sign up

Export Citation Format

Share Document